Jakob Riis (Chairman)

President and CEO, Falck

Prior to taking up his role as President and CEO at Falck in 2017, Jakob Riis had been working at Novo Nordisk since 1996 in the area of health economics and disease management. In 2001 he took up a position within sales in the US, and moved from this position into a job as Marketing Director for Japan and Oceania. In 2005 Jakob returned to Headquarters to take up the position as senior vice president for global marketing.

In 2008 he was appointed senior vice president and project vice president for liraglutide, responsible for the approval, production and commercialisation of Victoza® (liraglutide). In 2010 the liraglutide organisation was remerged into global marketing and Jakob Riis was appointed senior vice president of global marketing & 
global medical affairs, heading up two major global launches (insulin Degludec and DegludecAspart). In 2013 he became an EVP and joined the Executive Management team.

Jakob Riis holds a MSc in Forestry (1992) and a PhD in Econometrics (1996) from Faculty of Life Sciences, University of Copenhagen.